Aveo teams with Bristol Myers after surprise FDA approval; CalciMedica lines up $21M raise to advance Covid-19 candidate
Aveo Oncology’s newly approved drug doesn’t extend lives, but hey, maybe it will when combined with Opdivo?
Aveo announced Friday that it was launching a trial to test tivozanib with Bristol Myers Squibb’s checkpoint therapy in renal cell carcinoma in a Phase III trial, betting that combining the kinase inhibitor and an immunotherapy could lead to a better outcome for patients.
The announcement comes two days after the FDA approved the drug for the same indication. It was a surprise, coming 9 years after the company first filed for approval, and after a pivotal trial showed patients who got the placebo lived 3 months longer than patients who got the drug. (Aveo, defending the drug, has said the hazard ratio for death is 0.97 and pointed to the progression-free survival figures for patients who got the drug.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.